Literature DB >> 25175064

Gold drug auranofin could reduce neuroinflammation by inhibiting microglia cytotoxic secretions and primed respiratory burst.

Jocelyn M Madeira1, Ekta Bajwa1, Maegan J Stuart1, Sadayuki Hashioka2, Andis Klegeris3.   

Abstract

Neuroinflammation contributes to the pathogenesis of neurological disorders. Anti-inflammatory treatments could potentially be used to slow down the progression of these diseases. We studied the anti-neuroinflammatory activity of gold compounds which have been used to treat rheumatoid arthritis. Non-toxic concentrations of auranofin (0.1-1 μM) significantly reduced the cytotoxic secretions by primary human microglia and microglia-like THP-1 promonocytic cells. Auranofin inhibited primed NADPH-oxidase dependent respiratory burst and secretion of tumor necrosis factor (TNF)-α and nitric oxide by monocytic cells. It had a direct neuroprotective effect on SH-SY5Y neuronal cells. Auranofin could have a novel application in the treatment of neurodegenerative diseases.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Aurothiomalate; Aurothiosulfate; Neuroprotection; Parkinson's disease; Respiratory burst priming

Mesh:

Substances:

Year:  2014        PMID: 25175064     DOI: 10.1016/j.jneuroim.2014.08.615

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

Review 1.  Gold-based therapy: From past to present.

Authors:  Alice Balfourier; Jelena Kolosnjaj-Tabi; Nathalie Luciani; Florent Carn; Florence Gazeau
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-08       Impact factor: 11.205

2.  Integrative Analysis of Motor Neuron and Microglial Transcriptomes from SOD1G93A Mice Models Uncover Potential Drug Treatments for ALS.

Authors:  Elif Kubat Oktem; Busra Aydin; Metin Yazar; Kazim Yalcin Arga
Journal:  J Mol Neurosci       Date:  2022-09-30       Impact factor: 2.866

3.  Auranofin: repurposing an old drug for a golden new age.

Authors:  Christine Roder; Melanie J Thomson
Journal:  Drugs R D       Date:  2015-03

Review 4.  A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases.

Authors:  Jocelyn M Madeira; Stephanie M Schindler; Andis Klegeris
Journal:  Neural Regen Res       Date:  2015-03       Impact factor: 5.135

Review 5.  Drug repurposing screens and synergistic drug-combinations for infectious diseases.

Authors:  Wei Zheng; Wei Sun; Anton Simeonov
Journal:  Br J Pharmacol       Date:  2017-07-09       Impact factor: 8.739

6.  In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.

Authors:  Ziyan Y Pessetto; Bin Chen; Hani Alturkmani; Stephen Hyter; Colleen A Flynn; Michael Baltezor; Yan Ma; Howard G Rosenthal; Kathleen A Neville; Scott J Weir; Atul J Butte; Andrew K Godwin
Journal:  Oncotarget       Date:  2017-01-17

7.  Repurposing Auranofin, an Anti-Rheumatic Gold Compound, to Treat Acne Vulgaris by Targeting the NLRP3 Inflammasome.

Authors:  Gabsik Yang; Seon Joo Lee; Han Chang Kang; Yong-Yeon Cho; Hye Suk Lee; Christos C Zouboulis; Sin-Hee Han; Kyung-Ho Ma; Jae-Ki Jang; Joo Young Lee
Journal:  Biomol Ther (Seoul)       Date:  2020-09-01       Impact factor: 4.634

8.  Unraveling Targetable Systemic and Cell-Type-Specific Molecular Phenotypes of Alzheimer's and Parkinson's Brains With Digital Cytometry.

Authors:  Marie C Bordone; Nuno L Barbosa-Morais
Journal:  Front Neurosci       Date:  2020-12-09       Impact factor: 4.677

9.  Neuroprotective effects of some epigenetic modifying drugs' on Chlamydia pneumoniae-induced neuroinflammation: A novel model.

Authors:  Elif Kaya-Tilki; Miriş Dikmen
Journal:  PLoS One       Date:  2021-11-30       Impact factor: 3.240

10.  Early retinal inflammatory biomarkers in the middle cerebral artery occlusion model of ischemic stroke.

Authors:  Rodney M Ritzel; Sarah J Pan; Rajkumar Verma; John Wizeman; Joshua Crapser; Anita R Patel; Richard Lieberman; Royce Mohan; Louise D McCullough
Journal:  Mol Vis       Date:  2016-06-04       Impact factor: 2.367

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.